Antibody Identified that Can Prevent Heart Blockages
By Biotechdaily staff writers
Posted on 28 Jan 2003
A new antibody, Anti-gp38k, has been identified that binds to and inhibits the glycoprotein (gp38k) that causes the stimulation and migration of cells that cause blockages in coronary arteries. The antibody may also inhibit the migration of breast cancer cells.Posted on 28 Jan 2003
The cell aggregation properties of the glycoprotein gp38k were first identified in 1995 by Albert Millis, Ph.D., chairman of the biologic sciences department of New York University at Albany (NY, USA), and some of his pre-doctoral students. Subsequent experiments resulted in an understanding of its role in vascular cell migration and the development of Anti-gp38k, patented in 2002 as a therapy for occlusive blood vessel disease.
"The protein is a potent inhibitor of vascular cell migration, suggesting that its use might prevent occlusive vascular disease before it begins,” said Dr. Mills. Although the antibody has not yet been tested clinically, its properties of inhibiting the movement of certain cells also have shown preliminary promise for the treatment of cancer. In particular, it appears to inhibit the migration of breast cancer cells.
Related Links:
NYU, Albany
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Homocysteine Quality Control
Liquichek Homocysteine Control
